nvro-8k_20200521.htm
false 0001444380 0001444380 2020-05-21 2020-05-21

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 21, 2020

 

NEVRO CORP.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-36715

 

56-2568057

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

 

1800 Bridge Parkway

Redwood City, CA 94065

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 251-0005

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol

 

Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

NVRO

 

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.07Submission of Matters to a Vote of Security Holders.

On May 21, 2020, Nevro Corp. (the “Company”) held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 9, 2020. Only stockholders of record as of the close of business on March 27, 2020, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 32,020,072 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

Proposal 1. The election of three directors to hold office until the 2021 annual meeting of stockholders or until their respective successor is elected:

 

Nominee

 

Votes For

 

 

Votes Withheld

 

 

Broker

Non-Votes

 

Frank Fischer

 

 

18,412,581

 

 

 

8,427,978

 

 

 

1,636,715

 

Shawn T McCormick

 

 

26,548,686

 

 

 

291,873

 

 

 

1,636,715

 

Kevin O’Boyle

 

 

26,558,220

 

 

 

282,339

 

 

 

1,636,715

 

Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors of the Company, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2020:

 

Votes For

 

 

Votes Against

 

 

Abstentions

 

 

28,415,055

 

 

 

58,454

 

 

 

3,765

 

As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

Proposal 3. The approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers:

 

Votes For

 

 

Votes Against

 

 

Abstentions

 

 

Broker Non-Votes

 

 

25,225,657

 

 

 

1,581,703

 

 

 

33,199

 

 

 

1,636,715

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

NEVRO CORP.

 

 

 

 

 

Date: May 26, 2020

 

  By:

 

    /s/ Andrew H. Galligan

 

 

 

 

    Andrew H. Galligan

 

 

 

 

    Chief Financial Officer